
Alan Brown, MD, Columbia University’s Mailman School of Public Health, New York, New York, and colleagues conducted an analysis of data from the Finnish Prenatal Study of Schizophrenia, a large, national birth cohort with an extensive bio-bank. They tested for the presence of C-reactive protein in the maternal blood of 777 offspring with schizophrenia and compared the findings with those from 777 control subjects. Maternal C-reactive protein levels were assessed from archived maternal serum specimens.
They found that increasing maternal C-reactive protein levels were significantly associated with development of schizophrenia in offspring and remained significant after adjusting for potential confounders such as parental history of psychiatric disorders, twin/singleton birth, location of birth, and maternal socioeconomic status.
For every 1 mg/L increase in maternal C-reactive protein, the risk of schizophrenia increased by 28%.
“This is the first time that this association has been demonstrated, indicating that an infection or increased inflammation during pregnancy could increase the risk of schizophrenia in the offspring,” said Dr. Brown, MD.
“Inflammation has been shown to alter brain development in previous studies, and schizophrenia is a neurodevelopmental disorder,” he said. “Thus, this study provides an important link between inflammation and schizophrenia and may help us to better understand the biological mechanisms that lead to this disorder. To the extent that the increased inflammation is due to infection, this work may suggest that approaches aimed at preventing infection may have the potential to reduce risk of schizophrenia.”
There are many other known causes of inflammation, including tissue injury and autoimmune disease, although the researchers did not examine these specific conditions in their study.